OC
ICPT

Oppenheimer & Co’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Oppenheimer & Co’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,812
Closed -$240K – 1329
2020
Q1 		$240K Sell
3,812
-4,788
-56% -$430K 0.01% 979
2019
Q4 		$1.07M Sell
8,600
-314
-4% -$28.1K 0.03% 603
2019
Q3 		$592K Sell
8,914
-701
-7% -$47.1K 0.02% 733
2019
Q2 		$766K Buy
9,615
+4,712
+96% +$422K 0.02% 677
2019
Q1 		$548K Buy
4,903
+2,522
+106% +$276K 0.01% 783
2018
Q4 		$240K Sell
2,381
-425
-15% -$44.1K 0.01% 1040
2018
Q3 		$355K Sell
2,806
-3,661
-57% -$387K 0.01% 1001
2018
Q2 		$542K Sell
6,467
-13
-0.2% -$952 0.01% 830
2018
Q1 		$399K Buy
6,480
+1,585
+32% +$95.5K 0.01% 939
2017
Q4 		$286K Buy
4,895
+110
+2% +$6.94K 0.01% 1073
2017
Q3 		$278K Buy
4,785
+2,833
+145% +$305K 0.01% 1062
2017
Q2 		$237K Sell
1,952
-200
-9% -$23.2K 0.01% 1115
2017
Q1 		$244K Buy
2,152
+178
+9% +$20.8K 0.01% 1084
2016
Q4 		$214K Sell
1,974
-1,258
-39% -$150K 0.01% 1131
2016
Q3 		$532K Sell
3,232
-548
-14% -$86.4K 0.02% 790
2016
Q2 		$540K Sell
3,780
-294
-7% -$42.9K 0.02% 761
2016
Q1 		$524K Sell
4,074
-997
-20% -$118K 0.02% 736
2015
Q4 		$757K Sell
5,071
-1,316
-21% -$223K 0.02% 643
2015
Q3 		$1.06M Buy
6,387
+1,575
+33% +$346K 0.03% 563
2015
Q2 		$1.16M Buy
4,812
+698
+17% +$186K 0.03% 577
2015
Q1 		$1.16M Sell
4,114
-2,705
-40% -$586K 0.03% 589
2014
Q4 		$1.06M Buy
6,819
+3,044
+81% +$562K 0.03% 583
2014
Q3 		$893K Buy
3,775
+1,739
+85% +$443K 0.03% 636
2014
Q2 		$482K Sell
2,036
-15
-0.7% -$3.95K 0.01% 866
2014
Q1 		$677K Buy
+2,051
New +$692K 0.02% 730

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Oppenheimer & Co's ICPT Position: Q2 2020 in Review

Oppenheimer & Co sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2020, closing a stake of 3,812 shares — an estimated $240K sold.

Oppenheimer & Co first reported a position in ICPT in Q1 2014 and held it in 25 quarters. The position peaked at $1.16M in Q2 2015. 192 funds tracked by Wall St. Rank hold ICPT as of Q2 2020.

  • Oppenheimer & Co reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Oppenheimer & Co sold 3,812 Intercept Pharmaceuticals, Inc. shares in Q2 2020, an estimated $240K.
  • Oppenheimer & Co first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 25 quarters.
  • Oppenheimer & Co's Intercept Pharmaceuticals, Inc. position peaked at $1.16M in Q2 2015.
  • 192 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2020.

Based on Oppenheimer & Co's 13F filing for Q2 2020, filed 11 Aug 2020.